CPVI Plus Renal Sympathetic Modification Versus CPVI Alone for AF（Atrial Fibrillation） Ablation

Atrial Fibrillation Clinical Trial

Official title:

Circumferential Pulmonary Vein Isolation (CPVI) Plus Renal Sympathetic Modification Versus CPVI Alone for AF Ablation: a Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01686542
• Other study ID #: SWAN-cpAF
• Status: Recruiting
• Phase: N/A
• Start date: June 2012
• Est. completion date: June 2020

Study information

• Verified date: March 2019
• Source: The Second Affiliated Hospital of Chongqing Medical University
• Contact: Yuehui Yin, MD
• Phone: 0086-13508335502
• Email: yinyh63[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is designed as a randomized control trial. The purpose of this study is to observe the efficacy and safety of atrial fibrillation ablation, comparing circumferential pulmonary vein isolation (CPVI) plus renal sympathetic modification (RSM) with CPVI alone.

Description:

Basic studies suggested that sympathetic nerves over-activity played an important role in the pathophysiological changes of arrhythmia occurrence. Present studies of renal ablation show a new method to decrease sympathetic nerves activity. Circumferential pulmonary vein isolation (CPVI) is an accepted ablation method for atrial fibrillation. The investigators plan to evaluate the efficiency and safety of CPVI plus renal sympathetic modification for atrial fibrillation ablation comparing with CPVI alone. The trial is going to recruit 100 patients randomized into two groups (CPVI+RSM group VS CPVI group = 50:50) with a follow-up duration of 4 years. The investigators aim to observe the relapse of atrial tachyarrhythmia lasting more than 30 seconds, the incidence of composite cardiovascular events after renal sympathetic modification, and safety and efficacy of the intervention, comparing with CPVI alone.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: June 2020
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• • = 18 years old, and = 75 years old of age

• more than half a year history of atrial fibrillation, no matter paroxysmal or persistent, with clinical symptom or ECG proved

• be ineffective to at least one kind of anti-arrhythmic drugs treatment

• echocardiography has done to except structural heart diseases such as congenital, valvular heart diseases and kinds of cardiomyopathy

• estimated glomerular filtration rate (eGFR) of = 45ml/min

• is competent and willing to provide written, informed consent to participate in this clinical study

Exclusion Criteria:

• • transesophageal echocardiography found thrombus in left atrial appendage

• past history of atrial fibrillation surgical maze procedure

• estimated glomerular filtration rate (eGFR) of < 45mL/min

• has the history of renal restenosis or renal stents implantation

• has experienced AMI(acute myocardial infarction) (old myocardial infarction is not excluded), unstable angina pectoris, cerebrovascular accidents, and alimentary tract hemorrhage within 3 months

• patients with sick sinus syndrome

• pregnant women

• mental disorders

• patients that have allergy to contrast agent

• patients that do not go with follow-up

• others such as researcher considers it is not appropriate to be included into the study

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Procedure:
• CPVI plus renal sympathetic modification
CPVI plus renal denervation to reduce atrial arrhythmia recurrence.
• CPVI
CPVI alone to reduce atrial arrhythmia recurrence.

Locations

Country	Name	City	State
China	2ndChongqingMU	Chongqing	Chongqing

Sponsors (1)

Lead Sponsor	Collaborator
The Second Affiliated Hospital of Chongqing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The relapse rate of atrial tachyarrhythmia	Atrial tachyarrhythmia lasting more than 30 seconds consider relapsed	Four years